CellaVision is to acquire RAL Diagnostics
CellaVision AB has signed an agreement to acquire the French company RAL Diagnostics (RAL), which manufactures sample preparation products in hematology, pathology, cytology and microbiology. RAL’s sales in 2018 was about SEK 87 million and its EBITDA margin about 15 percent. The cash purchase price is SEK 268 million on a cash and debt-free basis. The acquisition is financed through a combination of CellaVision’s own cash and cash equivalents and bank loans arranged by Skandinaviska Enskilda Banken of SEK 120 million.
The acquisition of RAL is a natural step in CellaVision’s established strategy
The acquisition of RAL gives CellaVision the ability to further improve the quality of sample preparation, which is of great importance for the result of the blood analysis. The quality of the sample preparation is important for optimal functioning of CellaVision’s systems, and there is a great need in both large, small and mid-size laboratories for standardized solutions.
This acquisition gives CellaVision a well-established brand with solutions in staining and sample preparation of the highest quality. CellaVision and RAL together create an increased customer value in digital morphology by offering a complete and integrated solution for the hematology laboratory.